Head of Creative and Corporate Branding

United States

Auto‑apply with AI Apply

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biopharmaceuticals, HealthcareIndustries

Requirements

Candidates should possess a Bachelor’s degree in graphic design, branding, marketing, communications, or a related field, and a minimum of 12 years of experience in creative leadership roles, including healthcare and corporate branding. They must also have at least 3 years of direct management experience, along with knowledge of regulatory requirements and compliance in pharmaceutical marketing.

Responsibilities

The Head of Creative and Corporate Branding will develop and execute innovative creative strategies, lead and inspire design teams, establish corporate brand guidelines, oversee the design of corporate materials and campaigns, collaborate with various functions, and ensure cohesive messaging and branding consistency. They will also interface with c-suite executives, oversee the creative process, stay updated with industry trends, build relationships with partners, and present ideas clearly and persuasively to the organization.

Skills

Creative Strategy

Branding

Design Leadership

Healthcare Industry Knowledge

Regulatory Compliance

Cross-functional Collaboration

Communication

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free